Patent ID: 8835420

Claim:
A compound of Formula 1, or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from C 3-8 cycloalkyl, C 2-6 heterocyclyl, C 6-14 aryl, and C 1-9 heteroaryl, each optionally substituted with from one to five substituents independently selected from halo, oxo, —CN, R 11 , and R 12 ; R 2 , R 4 , and R 5 are each independently selected from hydrogen, halo, —OH, —CN, C 1-3 alkyl, and C 1-3 haloalkyl; R 3 is selected from hydrogen, C 1-3 alkyl, and C 1-3 haloalkyl; R 6 and R 7 are each independently selected from hydrogen, C 1-3 alkyl, and C 1-3 haloalkyl; R 8 is selected from hydrogen, methyl, and —NH 2 ; R 9 is selected from hydrogen, halo, —CN, C 1-3 haloalkyl, —OR 16 , —C(O)R 16 , —C(O)OR 16 , —C(O)N(R 16 )R 17 , —C(O)N(R 16 )OR 17 , —C(O)N(R 16 )S(O) 2 R 18 , SR 16 , —S(O)R 18 , —S(O) 2 R 18 , and —S(O) 2 N(R 16 )R 17 ; or R 8 is selected from —NH— and —CH 2 —, and R 8 and R 9 , together with the carbon atoms to which they are attached, form a C 2-4 heteroarylene having 5 ring atoms and 1 to 3 heteroatoms, each of the heteroatoms being nitrogen, and wherein the C 2-4 heteroarylene is optionally substituted with R 12 ; R 10 is selected from halo, —OH, C 1-3 alkyl, —NHR 16 , and —NHC(O)R 16 ; each R 11 is independently selected from —OR 13 , —N(R 13 )R 14 , —NR 13 C(O)R 14 , —NHC(O)NR 13 R 14 , —NR 13 C(O)NHR 14 , —C(O)R 13 , —C(O)OR 13 , —C(O)N(R 13 )R 14 , —C(O)N(R 13 )OR 14 , —C(O)N(R 13 )S(O) 2 R 12 , —N(R 13 )S(O) 2 R 12 , —SR 13 , —S(O)R 12 , —S(O) 2 R 12 , and —S(O) 2 N(R 13 )R 14 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl-(CH 2 ) m —, C 6-14 aryl-(CH 2 ) m —, C 2-6 heterocyclyl-(CH 2 ) m —, and C 1-9 heteroaryl-(CH 2 ) m —, each optionally substituted with from one to five substituents independently selected from halo, oxo, —CN, C 1-6 alkyl, C 1-6 haloalkyl, and R 15 ; each R 13 and R 14 is independently selected from (a) hydrogen; and (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl-(CH 2 ) m —, C 6-14 aryl-(CH 2 ) m —, C 2-6 heterocyclyl-(CH 2 ) m —, and C 1-9 heteroaryl-(CH 2 ) m —, each optionally substituted with from one to five substituents independently selected from halo, oxo, —CN, C 1-6 alkyl, C 1-6 haloalkyl, and R 15 ; each R 15 is independently selected from −OR 16 , —N(R 16 )R 17 , —N(R 16 )C(O)R 17 , —NHC(O)NR 16 R 17 , —NR 16 C(O)NHR 17 , —C(O)R 16 , —C(O)OR 16 , —C(O)N(R 16 )R 17 , —C(O)N(R 16 )OR 17 , —C(O)N(R 16 )S(O) 2 R 18 , —NR 16 S(O) 2 R 18 , —SR 16 , —S(O)R 18 , —S(O) 2 R 18 , and —S(O) 2 N(R 16 )R 17 ; each R 16 and R 17 is independently selected from hydrogen, C 1-6 alkyl, and C 3-6 cycloalkyl; each R 18 is independently selected from C 1-6 alkyl and C 3-6 cycloalkyl; each m is independently selected from 0, 1, 2, 3, and 4; wherein each of the aforementioned heteroaryl moieties independently has 1 to 4 heteroatoms independently selected from N, O, and S, and each of the aforementioned heterocyclyl moieties independently has 1 to 4 heteroatoms independently selected from N, O, and S.